Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stratified Treatment of Ph+ ALL Guided by Multimodal MRD Monitoring (Huaxi Protocol 2024 vs 2016)
ChiCTR2600126815Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dasatinib, olverembatinib, blinatumomab and tretinoin in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Progression-Free Survival (PFS), MRD negativity rate at 1 month post-induction therapy and 2 more. Started Jun 2026; status: recruiting.
02
Drugs
dasatinibolverembatinibblinatumomabtretinoin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2600126815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126815.